Login to Your Account


Angiochem peptide drug conjugate enters phase IIb in HER2+ breast cancer

By Marie Powers
Staff Writer

Friday, May 30, 2014

Despite rumors to the contrary, news coming from the American Society of Clinical Oncology (ASCO) meeting in Chicago was not entirely focused on immunotherapy. Privately held Angiochem Inc. was among the companies reporting positive findings from candidates with other mechanisms of action. Angiochem's lead molecule, ANG1005, is a paclitaxel-peptide drug conjugate and the first drug of its kind to leverage the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. At ASCO, the company reported findings from phase I and initial phase II studies in HER2+ and HER2-negative breast cancer.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription